{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T22:25:57Z","timestamp":1749853557968,"version":"3.41.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T00:00:00Z","timestamp":1449532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s40272-015-0157-x","type":"journal-article","created":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T08:52:50Z","timestamp":1449651170000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prescribing Ceftolozane\/Tazobactam for Pediatric Patients: Current Status and Future Implications"],"prefix":"10.1007","volume":"18","author":[{"given":"Seetha M.","family":"Tamma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice J.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranita D.","family":"Tamma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,8]]},"reference":[{"key":"157_CR1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","volume":"56","author":"HW Boucher","year":"2013","unstructured":"Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10\u00a0\u00d7\u00a0\u203220 Progress\u2013development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1685\u201394.","journal-title":"Clin Infect Dis"},{"key":"157_CR2","unstructured":"Generating Antibiotic Incentives Now Act of 2011. https:\/\/www.congress.gov\/bill\/112th-congress\/house-bill\/2182 . Accessed 28 Nov 2015."},{"key":"157_CR3","unstructured":"Antibiotic Development to Advance Patient Treatment Act of 2013. https:\/\/www.congress.gov\/bill\/113th-congress\/house-bill\/3742 . Accessed 28 Nov 2015."},{"key":"157_CR4","unstructured":"ZERBAXA (ceftolozane\/tazobactam) Current Prescribing Information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206829lbl.pdf . Accessed 28 Nov 2015."},{"key":"157_CR5","unstructured":"Europeans Medicines Agency. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003772\/human_med_001917.jsp&mid=WC0b01ac058001d124 . Accessed 28 Nov 2015."},{"key":"157_CR6","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1128\/AAC.00296-10","volume":"54","author":"B Moya","year":"2010","unstructured":"Moya B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:3933\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","volume":"74","author":"GG Zhanel","year":"2014","unstructured":"Zhanel GG, Chung P, Adam H, et al. Ceftolozane\/tazobactam: a novel cephalosporin\/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31\u201351.","journal-title":"Drugs"},{"key":"157_CR8","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.06349-11","volume":"56","author":"B Miller","year":"2012","unstructured":"Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. Pharmacokinetics and safety of intravenous ceftolozane\/tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012;56:3086\u201391.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR9","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/AAC.01590-12","volume":"57","author":"WA Craig","year":"2013","unstructured":"Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013;57:1577\u201382.","journal-title":"Antimicrob Agents Chemother"},{"issue":"57","key":"157_CR10","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1128\/AAC.00656-13","volume":"2013","author":"B Vanscoy","year":"2013","unstructured":"Vanscoy B, Mendes RE, McCauley J, et al. Pharmacological basis of \u03b2-lactamase inhibitor therapeutics: tazobactam in combination with cefolozane. Antimicrob Agents Chemother. 2013;2013(57):5924\u201331.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR11","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1128\/AAC.02151-13","volume":"58","author":"M Wooley","year":"2014","unstructured":"Wooley M, Miller B, Krishna G, Hershberger E, Chandorkar G. Impact of renal function on the pharmacokinetics and safety of ceftolozane\/tazobactam. Antimicrob Agents Chemother. 2014;58:2249\u201355.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR12","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"J Solomkin","year":"2015","unstructured":"Solomkin J, Hershberger E, Miller B, et al. Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462\u201371.","journal-title":"Clin Infect Dis"},{"key":"157_CR13","unstructured":"Pharmacokinetic and safety study of ceftolozane\/tazobactam in pediatric participants receiving antibiotic therapy for proven or suspected gram-negative infection or for peri-operative prophylaxis (MK-7625A-010). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02266706 . Accessed 28 Nov 2015."},{"key":"157_CR14","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1128\/AAC.38.12.2817","volume":"38","author":"MD Reed","year":"1994","unstructured":"Reed MD, Goldfarb J, Yamashita TS, et al. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother. 1994;38:2817\u201326.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR15","unstructured":"Safety and efficacy study of ceftolozane\/tazobactam to treat ventilated nosocomial pneumonia (ASPECT-NP). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02070757 . Accessed 28 Nov 2015."},{"key":"157_CR16","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1093\/jac\/dks246","volume":"67","author":"G Chandorkar","year":"2012","unstructured":"Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O. Intrapulmonary penetration of ceftolozane\/tazobactam and piperacillin\/tazobactam in healthy adult subjects. J Antimicrob Chemother. 2012;67:2463\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"157_CR17","doi-asserted-by":"crossref","unstructured":"Xiao AJ, Miller BW, Huntington JA, et al. Ceftolozane\/tazobactam pharmacokinetic\/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2015. doi: 10.1002\/jcph.566 . [Epub ahead of print].","DOI":"10.1002\/jcph.566"},{"key":"157_CR18","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1128\/AAC.04402-14","volume":"59","author":"MJ Melchers","year":"2015","unstructured":"Melchers MJ, Mavridou E, Seyedmousavi S, et al. Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice. AAC. 2015;59:3373\u20136.","journal-title":"AAC"},{"key":"157_CR19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/civ411","volume":"61","author":"MS Gelfand","year":"2015","unstructured":"Gelfand MS, Cleveland KO. Ceftolozane\/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2015;61:853\u20135.","journal-title":"Clin Infect Dis"},{"key":"157_CR20","unstructured":"Population pharmacokinetics and safety of intravenous ceftolozane\/tazobactam in adult cystic fibrosis patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02421120 . Accessed 28 Nov 2015."},{"key":"157_CR21","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1128\/AAC.02253-13","volume":"58","author":"DR Snydman","year":"2014","unstructured":"Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane\/tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2014;58:1218\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR22","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","volume":"58","author":"C Lucasti","year":"2014","unstructured":"Lucasti C, Hershberger E, Miller B, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane\/tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58:5350\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","volume":"50","author":"JS Solomkin","year":"2010","unstructured":"Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133\u201364.","journal-title":"Clin Infect Dis"},{"key":"157_CR24","unstructured":"Centers for diseases control and prevention. Get smart for healthcare. http:\/\/www.cdc.gov\/getsmart\/healthcare\/implementation\/core-elements.html . Accessed 28 Nov 2015."},{"issue":"Suppl 1","key":"157_CR25","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1086\/647940","volume":"50","author":"DR Snydman","year":"2010","unstructured":"Snydman DR, Jacobus NV, McDermott LA, et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005\u20132007). Clin Infect Dis. 2010;50(Suppl 1):S26\u201333.","journal-title":"Clin Infect Dis"},{"key":"157_CR26","unstructured":"Package insert for Zosyn (Piperacillin and tazobactam for injection, USP). http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=416 . Accessed 28 Nov 2015."},{"key":"157_CR27","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1128\/AAC.00046-15","volume":"59","author":"JM Smith","year":"2015","unstructured":"Smith JM, Avdic E, Tamma PD, et al. Risk factors for resistance to \u03b2-lactam\/\u03b2-lactamase inhibitors and ertapenem in Bacteroides bacteremia. Antimicrob Agents Chemother. 2015;59:5049\u201351.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR28","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","volume":"69","author":"HS Sader","year":"2014","unstructured":"Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u201312). J Antimicrob Chemother. 2014;69:2713\u201322.","journal-title":"J Antimicrob Chemother"},{"key":"157_CR29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","volume":"43","author":"DJ Farrell","year":"2014","unstructured":"Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014;43:533\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"157_CR30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2014.04.004","volume":"69","author":"HS Sader","year":"2014","unstructured":"Sader HS, Farrell DJ, Flamm RK, Jones RN. Ceftolozane\/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect. 2014;69:266\u201377.","journal-title":"J Infect"},{"key":"157_CR31","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","volume":"57","author":"DJ Farrell","year":"2013","unstructured":"Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane\/tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in US Hospitals (2011\u20132012). Antimicrob Agents Chemother. 2013;57:6305\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR32","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1128\/AAC.01404-13","volume":"57","author":"A Walkty","year":"2013","unstructured":"Walkty A, Karlowsky JA, Adam H, et al. In vitro activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother. 2013;57:5707\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR33","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","volume":"54","author":"K Bush","year":"2010","unstructured":"Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969\u201376.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR34","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1128\/AAC.37.4.851","volume":"37","author":"K Bush","year":"1993","unstructured":"Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother. 1993;37:851\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR35","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/AAC.00218-06","volume":"50","author":"O Zimhony","year":"2006","unstructured":"Zimhony O, Chmelnitsky I, Bardenstein R, et al. Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother. 2006;50:3179\u201382.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR36","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.45.12.3548-3554.2001","volume":"45","author":"KS Thomson","year":"2001","unstructured":"Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2001;45:3548\u201354.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR37","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","volume":"60","author":"PD Tamma","year":"2015","unstructured":"Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis. 2015;60:1319\u201325.","journal-title":"Clin Infect Dis"},{"key":"157_CR38","doi-asserted-by":"crossref","unstructured":"Ofer-Friedman H, Shefler C, Sharma S, et al. Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Infect Control Hosp Epidemiol. 2015;36(8):981\u20135.","DOI":"10.1017\/ice.2015.101"},{"key":"157_CR39","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane\/tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949\u201356.","journal-title":"Lancet"},{"key":"157_CR40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1517\/14656566.2015.994504","volume":"16","author":"C Eckmann","year":"2015","unstructured":"Eckmann C, Solomkin J. Ceftolozane\/tazobactam for the treatment of complicated intra-abdominal infections. Expert Opin Pharmacother. 2015;16:271\u201380.","journal-title":"Expert Opin Pharmacother"},{"key":"157_CR41","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","volume":"58","author":"G Cabot","year":"2014","unstructured":"Cabot G, Bruchmann S, Mulet X, et al. Pseudomonas aeruginosa ceftolozane\/tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother. 2014;58:3091\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR42","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dkq248","volume":"65","author":"DM Livermore","year":"2010","unstructured":"Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010;65:1972\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"157_CR43","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","volume":"51","author":"S Takeda","year":"2007","unstructured":"Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2007;51:826\u201330.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ijantimicag.2009.03.021","volume":"34","author":"DM Livermore","year":"2009","unstructured":"Livermore DM, Mushtaq S, Ge Y, Warner M. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents. 2009;34:402\u20136.","journal-title":"Int J Antimicrob Agents"},{"key":"157_CR45","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1128\/AAC.03681-14","volume":"58","author":"M Castanheira","year":"2014","unstructured":"Castanheira M, Mills JC, Farrell DJ, Jones RN. Mutation-driven beta-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from US hospitals. Antimicrob Agents Chemother. 2014;58:6844\u201350.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR46","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1128\/AAC.00461-13","volume":"57","author":"B VanScoy","year":"2013","unstructured":"VanScoy B, Mendes RE, Castanheira M, et al. Relationship between ceftolozane\u2013tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother. 2013;57:4134\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"157_CR47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diagmicrobio.2015.04.012","volume":"83","author":"JL Kuti","year":"2015","unstructured":"Kuti JL, Pettit RS, Neu N, et al. Microbiological activity of ceftolozane\/tazobactam, ceftazidime, meropenem, and piperacillin\/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis. Diagn Microbiol Infect Dis. 2015;83:53\u20135.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"157_CR48","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1469-0691.2010.03130.x","volume":"16","author":"L Zamorano","year":"2010","unstructured":"Zamorano L, Juan C, Fernandez-Olmos A, Ge Y, Canton R, Oliver A. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010;16:1482\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"157_CR49","unstructured":"Regulation (EC) No 1901\/2006 of the european parliament and of the council of 12 December 2006. http:\/\/ec.europa.eu\/health\/files\/eudralex\/vol-1\/reg_2006_1901\/reg_2006_1901_en.pdf . Accessed 28 Nov 2015."},{"key":"157_CR50","unstructured":"United states food and drug administration. Pediatric development of the drug or biological product. http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM338453.pdf . Accessed 28 Nov 2015."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-015-0157-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-015-0157-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-015-0157-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T18:17:36Z","timestamp":1748715456000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-015-0157-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,8]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["157"],"URL":"https:\/\/doi.org\/10.1007\/s40272-015-0157-x","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"type":"print","value":"1174-5878"},{"type":"electronic","value":"1179-2019"}],"subject":[],"published":{"date-parts":[[2015,12,8]]}}}